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Abstract
Short-chain fatty acids (SCFAs) are increasingly being monitored to elucidate the link between gut health and disease. These
metabolites are routinely measured in faeces, but their determination in serum is more challenging due to their low concentra-
tions. A method for the determination of eight SCFAs in serum is described here. High-resolution mass spectrometry and gas
chromatography were used to identify the presence of isomeric interferences, which were then overcome through a combination
of chromatographic separation and judicious choice of MS fragment ion. The SCFAs were derivatised to form 3-
nitrophenylhydrazones before being separated on a reversed-phase column and then detected using liquid chromatography
tandem mass spectrometry (LC-QQQ-MS). The LODs and LOQs of SCFAs using this method were in the range 1 to
7 ng mL−1 and 3 to 19 ng mL−1, respectively. The recovery of the SCFAs in serum ranged from 94 to 114% over the three
concentration ranges tested.
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Introduction
Short-chain fatty acids (SCFAs) are the end products of fermen-
tation of dietary fibre by anaerobic intestinal microbiota. As
humans lack the enzymes to degrade the bulk of dietary fibres,
nondigestible carbohydrates pass the upper gastrointestinal tract
unaffected and are fermented in the caecum and the large intes-
tine by the anaerobic caecal and colonic microbiota.
Fermentation results in multiple groups of metabolites including
the SCFAs [1]. SCFAs are saturated aliphatic organic acids that
consist of one to six carbons of which acetic acid (C2), propionic
acid (C3), and butyric acid (C4) are the most abundant (95%).
The SCFAs produced in the caecum/large intestine are
absorbed in the colon and either utilised in colonocytes or
transported via the portal vein to reach the blood circulation
and other organs. Transported SCFAs act as substrates or sig-
nal molecules that provide a link between the diet, the micro-
biota, and the host, and mediate health benefits locally in the
gut and at the systemic level [2]. The amount and type of fibre
consumed have dramatic effects on the composition of the
intestinal microbiota and consequently on the type and
amount of SCFAs produced.
In humans, the effect of dietary fibre intake has been stud-
ied by measuring the SCFA concentrations in faeces and cal-
culating the total rate of SCFA excretion. Higher concentra-
tions of SCFAs in faeces have been positively associated with
a higher dietary intake of fibre [3]. However, faecal SCFA
concentrations do not reflect the concentration and production
rate of SCFAs in the intestine or the level of absorption of
SCFAs by the host. The distinct relationship between the level
of faecal SCFAs, the composition, and the ratio of the
intestinal microbiota and health is unclear [4]. To gain
more understanding of the link between nutritional dis-
orders, gut microbiota, and gut microbiota–derived me-
tabolites, it is important to accurately measure both
circulating/blood and faecal SCFAs.
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SCFA concentrations in the colon and faeces are relatively
easy to quantify as intestinal concentrations are in the millimolar
range. However, SCFA concentrations in plasma and serum are
considerably lower and range between 50 and 100 μmol L−1 for
acetate and 0.5–10 μmol L−1 for propionate and butyrate [5].
Thus, themeasurement of SCFAs in serum at these concentrations
is more complicated and prone to interferences.
Traditionally, gas chromatography (GC) is the technique of
choice for the analysis of SCFAs [5–8]. However, recently, several
LC-MSmethods have been reported for the analysis of SCFAs [5,
9–13]. The SCFAs are typically derivatised as the low molecular
weight of the native SCFAs makes them susceptible to interfer-
ence when using MS detection, and also results in low recovery
due to their volatility. Derivatisation has the added advantage of
reducing the polarity of the SCFAs and making them more ame-
nable to retention on a reversed-phase column.
Han et al. (2015) reported a novel derivatisation reagent, 3-
nitrophenylhydrazine (3-NPH), for the sensitive detection of
SCFAs by LC-MS. The method was fully validated, and the
authors reported good sensitivity and importantly excellent
chemical stability of the derivatives [9]. As greater detection
sensitivity is required for serum and plasma samples com-
pared to faecal samples, Zeng and Cao (2018) investigated
several derivatisation reagents to determine which one provid-
ed maximum analyte sensitivity and optimal separation of the
SCFAs and ketone bodies in mouse serum from interfering
structural isomers [10].While they recommended the use of o-
benzylhydroxylamine (O-BHA) as a derivatising reagent for
the simultaneous determination of SCFAs and ketone bodies,
they did report superior sensitivity for the SCFAs when
derivatised with 3-NPH compared to O-BHA. Song et al.
(2019) also used LC-MS to monitor the concentrations of
SCFAs in mouse plasma but used 4-acetamido-7-mercapto-
2,1,3-benzoxadiazole as the derivatising reagent. While the
derivatisation method had the advantage of being completed
at room temperature, the excessive chromatographic run time
of 65 min for baseline resolution of the isomeric structures
was a serious limitation [13]. Therefore, in this work, we
chose to use 3-NPH to convert SCFAs to their 3-
nitrophenylhydrazones under optimised conditions for their
accurate quantification in human serum using LC-MS/MS.
Additionally, we report the use of GC and LC both coupled
to a high-resolution mass spectrometry as orthogonal methods
that use fundamentally different principles (detection or sepa-
ration) to inform the development of an LC-MS/MS method.
Materials and methods
Chemicals and reagents
LC-MS-grade water and acetonitrile (ACN) were purchased
from Thermo Fisher Scientific (Sydney, Australia). Butyric
acid-D7 was purchased from Cambridge Isotope
Laboratories (Cambridge, MA, USA). Acetic acid, propionic
acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid,
4-methyl valeric acid, hexanoic acid, 13C2-acetic acid, 2-
ethylbutyric acid, methyl tert-butyl ether (MTBE), 3-
nitrophenylhydrazine hydrochloride (3-NPH.HCl), 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC.HCl), and pyridine were all purchased from Sigma-
Aldrich (Sydney, Australia).
Preparation standards
Stock solutions of acetic acid, propionic acid, isobutyric acid,
butyric acid, isovaleric acid, valeric acid, 4-methylvaleric ac-
id, and hexanoic acid were prepared in 20%methanol/water at
concentrations of 10.5, 7.425, 1.455, 1.455, 9.6, 2.775, 2.769,
and 2.79 mg mL−1, respectively. Mixed calibration standard
solutions (eight) in the range 0.015–1 μg mL−1 for valeric
acid, 4-methylvaleric acid, and hexanoic acid; 0.0375–
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15–10 μg mL−1 for isovaleric acid; and 0.375–
25 μg mL−1 for acetic acid were prepared in water. Three
QC standards at 0.015, 0.1, and 1 μg mL−1 for valeric acid,
4-methylvaleric acid, and hexanoic acid; 0.0375, 0.25, and
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15, 1, and 10 μg mL−1 for isovaleric acid; and 0.375,
2.5, and 25 μg mL−1 for acetic acid were also prepared in
water.
The internal standards were prepared in water at a concen-
tration of 1 mg mL−1. Aliquots (2 mL) were stored at − 80 °C.
An internal standard solution containing the labelled internal
standards (13C2-acetic acid (35 μg mL
−1), D7-butyric acid
(3.84 μg mL−1), and 2-ethyl butyric acid (1 μg mL−1)) were
prepared in LC-MS-grade acetonitrile.
Serum samples
Briefly, venous blood samples were obtained from healthy
volunteers from the antecubital vein and collected in SST
vacutainer tubes (Becton Dickinson, NJ, USA). Serum sam-
ples were allowed to clot for at least 30 min at room temper-
ature, before subsequently being centrifuged at 1300g for
15 min. The supernatant was then immediately aliquoted
and stored at − 80 °C.
Sample preparation for LC-MS analysis
Serum was thawed and 200 μL was transferred to a 15-mL
polypropylene centrifuge tube. The ACN solution containing
internal standards (600 μL) was added to the thawed serum
samples, and the samples were allowed to sit on ice for
20 min. The ACN layer was separated by centrifuging the
samples at 4 °C (300g × 2 min) and transferred to a separate
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15-mL centrifuge tube, and 200 μL water was added to the
solution. The SCFAs were derivatised to alkyl hydrazones by
adding 600 μL of 200 mM 3-nitrophenylhydrazine hydro-
chloride (3-NPH-HCL) solution in 50% acetonitrile/water
and 600 μL of 120 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC.HCl) containing 6% pyri-
dine solution in 50% acetonitrile/water. The samples were
heated at 40 °C on a Reacti-block (Hangzhou Ruicheng,
China) for 30 min and then placed immediately on ice. The
SCFAs were then extracted with two sequential aliquots of
MTBE (5.0 mL and 4.0 mL). On each addition of MTBE,
the solution was gently mixed and then centrifuged at 4 °C
at (300g × 2 min). The combined MTBE extracts were dried
under nitrogen at room temperature, reconstituted with
200 μL of 10% acetonitrile/water, and filtered through 3-
kDa cut-off filters.
Calibration standards, QC standards, and extraction blanks
(water replaced the serum) were prepared using the same pro-
cedure as for the experimental samples.
Sample preparation for GC-HRAM-MS analysis
Serum samples were thawed and 200 μL of each sample was
transferred to separate 15-mL polypropylene tubes and stored
on ice. Ultra-high-purity water (200 μL) was used for a blank
sample. Internal standards were added to the samples: 57 μL
of 13C2-acetic acid solution (35 μg mL
−1); 83 μL butyric acid-
D7 (3.84 μg/mL); and 63 μL 2-ethylbutyric acid
(0.8 μg mL−1) and mixed well. The samples were then de-
proteinated by adding 50 μL of a 10% (w/w) sulfosalicylic
acid solution prepared in water. The samples were then
capped and left on ice for 20 min to cool and minimise possi-
ble losses of the released volatile SCFAs.
The SCFAs were extracted from the de-proteinated serum
samples with 3.0 mL cold MTBE (refrigerated at 4 °C). The
samples were vortexed and then centrifuged (300g × 2 min) to
separate the layers. TheMTBE layer was transferred to a clean
tube containing 50 μL of cold 0.2 M aqueous sodium hydrox-
ide solution to back extract the SCFAs into the aqueous layer.
After vortexing and centrifuging, the MTBE layer was
discarded. Cold phosphoric acid solution (30 μL, 1.0 M)
was then added to the samples and vortexed to mix. The sam-
ples were transferred to cold 2mLGC vials fitted with 200-μL
tapered glass inserts. The samples were diluted 1:5 or 1:8 with
cold high-purity water prior to analysis by GC–high-resolu-
tion accurate-mass (HRAM)–MS (GC-HRAM-MS).
LC-HRAM-MS analysis
A Thermo Scientific Ultimate 3000 Liquid Chromatography
coupled to a Thermo Scientific Q Exactive Focus Orbitrap
Mass Spectrometer was used to quantify the SCFAs in serum.
The pooled serum samples were separated on a Thermo
Hypersil aQ column and an ACE C18-PFP column, both hav-
ing dimensions of 100 mm × 2.1 mm ID and packed with
1.7 μm particles. Water (A) and ACN (B) were used for ana-
lyte separation. The initial mobile phase conditions were 99%
A and 1% B, held for 2 min. Solvent A was reduced to 90%
over 2 min, and then further reduced to 10% over 1 min and
held for 5 min before returning to initial conditions. The flow
rate was 0.2 mL min−1 and column temperature was main-
tained at 30 °C.
An ACE C18-AR column (100 mm× 2.1 mm ID; 1.7 μm
particle diameter) was also used to separate the SCFAs using
water (A) and acetonitrile (B)–based mobile phase. Initial
conditions were 80% A, held for 0.5 min. B was increased
to 30% over 6 min and then to 40% over 4.5 min. The mobile
phase was then increased to 95% B over 1.5 min and held for
2 min. The mobile phase was then returned to starting condi-
tions. The column was maintained at 45 °C and the flow rate
0.3 mL min−1. The sample injection volume was 2 μL.
Full-scan, single ion monitoring (SIM) and parallel reac-
tion monitoring (PRM) analyses were performed using a Q
Exactive Focus mass spectrometer. Electrospray ionisation in
the negative ion mode was used with a spray voltage of
2500 V, an auxiliary gas temperature of 350 °C, and a capil-
lary temperature of 350 °C. Full details of the MS settings for
all three modes are provided in the Supplementary
information.
GC-HRAM-MS analysis
A Thermo Fisher Scientific Q Exactive GC-MS instrument
was used to quantify SCFAs in serum extracts. A robotic
arm (Thermo Scientific ™ TriPlus™ RSH autosampler) was
used to inject 1 μL of sample into a split/splitless (SSL) injec-
tor at 230 °C using a 1:5 split flow on a Thermo Fisher
Scientific™ TRACE™ 1310 GC. Helium was used as the
carrier gas at a flow rate of 1.0 mLmin−1 with chromatograph-
ic separation on a Thermo Fisher Scientific TG-WAXMS A
column (30 m length × 0.25 mm inner diameter × 0.25 μm
film thickness column). The initial oven temperature was held
at 50 °C for 30 s, followed by a 30 °Cmin−1 temperature ramp
to 110 °C. The oven temperature was then ramped at
5 °C min−1 to 135 °C and then at 20 °C min−1 to a final
temperature of 230 °C and held for 2 min. The transfer line
temperature was set to 230 °C. Electron ionisation (EI) at
65 eV (positive polarity) and an emission current of 50 μA
with an ion source temperature of 250 °C were used in all
experiments. A filament delay of 5.0 min was used, and the
mass spectrometer was operated at a resolution of 120,000
(FWHM at m/z 200). Time-scheduled data acquisition for
the SCFAs was performed by 2 experiments: SIM for acetic
acid (5.5 to 7 min) and PRM (7 to 11 min) for the remaining
SCFAs. The ions monitored for SIM analysis and the
precursor-product transitions monitored in PRM in the
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inclusion list are summarised in Table S1. A collision energy
of 10 eV was used for all PRM transitions, and nitrogen was
used as the collision gas. A mass isolation window of 1.0 m/z
was used, and the maximum injection timewas set to “auto” in
both SIM and PRM experiments.
LC-QQQ-MS analysis
A Thermo Scientific Ultimate 3000 Liquid Chromatography
coupled to a Thermo Scientific TSQ Quantiva Triple
Quadrupole Mass Spectrometer was used for the validation
study. Detection was performed in negative mode (2500 V),
and the analytes were ionised by electrospray and monitored
in multiple reaction monitoring (MRM) mode. The LC con-
ditions were as described above for the ACEC18-AR column.
The MS conditions were gases (arbitrary units) sheath 50,
auxiliary 10, sweep 1, ion transfer tube temperature 325 °C,
and vaporiser temperature 350 °C. The ion transitions and
collision energies are presented in Table S2.
Method validation
Method validation was performed on LC-QQQ and in accor-
dance with ICH and IUPAC guidelines [14, 15].
Linearity, limit of detection, and limit of
quantification
Linearity was determined by constructing calibration curves
over the concentration range (0.015–1 μg mL−1 for valeric
acid, 4-methylvaleric acid, and hexanoic acid; 0.0375–
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15–10 μg mL−1 for isovaleric acid; and 0.375–
25 μg mL−1 for acetic acid) using each of the eight prepared
calibration standards (see “Preparation standards”). The limit
of detection (LOD) and limit of quantification (LOQ) of the
method were determined as a signal to noise ratio (S/N) of 3
and 10 of diluted standard solution, respectively.
Precision, trueness, and accuracy
Precision and trueness of the method were determined by an
intra-day and inter-day analysis of the calibration standards.
The calibration standards were injected 6 times per day (intra-
day) and 1 time per day for 6 consecutive days (inter-day).
The resulting peak area was used to calculate the coefficient of
variation (% CV) and thus precision. The calculated mean
concentration relative to the nominal concentration was used
to reveal trueness (% bias). Moreover, the relative standard
deviation (% RSD) of the obtained retention times for each
analyte for 12 injections was calculated to predict the retention
time repeatability of the method.
The accuracy of the method was evaluated by a recovery
test. In brief, three pooled serum samples (200 μL) were
spiked with 20 μL of mixed standard solutions at low
(LQC), medium (MQC), and high (HQC) levels of 0.058,
0.232, and 0.465 μg mL−1 for hexanoic acid; 0.058, 0.231,
and 0.462 μg/mL for 4-methyl valeric acid; 0.124, 0.495, and
1.238 μg mL−1 for propionic acid; 0.462, 2.308, and
4.615 μg mL−1 for isovaleric acid; 0.058, 0.233, and
0.465 μg/mL for valeric acid; 0.121, 0.485, and 1.213 μg/
mL for isobutyric acid; 0.120, 0.480, and 1.2 μg mL−1 for
butyric acid; and 0.525, 5.250, and 13.125 μg mL−1 for acetic
acid, respectively. The baseline (unspiked) and spiked serum
samples at each concentration were analysed, and the percent-
age of recovery was calculated according to Eq. (1), where
Cbaseline is the calculated unspiked analyte concentration,
Crecovered is the calculated spiked analyte concentration, and
Cspiked is the absolute concentration of spiked standard added
to the sample.




Chromatographic separation of SCFA
Pooled serum samples were derivatised to form 3-
nitrophenylhydrazones, and first separated on a Thermo
Hypersil aQ column, and analysed using high-resolution
Orbitrap mass spectrometry in three modes: full scan, SIM,
and PRM. For FS and SIM analysis, the precursor ion for each
analyte was used for quantification (Table S1). For PRM anal-
ysis, at least two product ions were monitored and the colli-
sion energy which gave the optimal signal for these product
ions was experimentally determined and adopted (Table S1).
The concentration of the SCFA in the pooled samples,
separated on the Hypersil aQ column and analysed by
HRAM-MS, was determined using a one-point calibration
using a standard solution with SCFA concentrations that
closely matched the expected concentration in serum and
using labelled and non-labelled internal standards (13C2-acetic
acid, butyric acid-D7, and 2-ethylbutyric acid). There was
good agreement between the three modes for all analytes, with
the exception of propionic acid (Table 1). The agreement be-
tween FS and SIM for propionic acid is expected as both
modes monitor the precursor ion. The lower concentration
reported using the PRM mode, when compared to SIM and
FS, suggests there is an isobaric interference with the precur-
sor ion resulting in elevated results for SIM and FS. In PRM
mode, quantification is determined using a fragment ion,
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which is monitored at high resolution providing extra selec-
tivity and hence resolution from coeluting background ions.
The chromatographic method using the Hypersil aQ col-
umn resolved the SCFAs (Fig. 1). Several isobaric or isomeric
compounds, and specifically those relating to the butyric and
valeric acids, present in the serum samples were also resolved
(Fig. 1). The fragmentation pattern and predicted elemental
composition for these interferences indicated they were likely
isomeric (see Supplementary information for MS/MS frag-
mentation pattern and elemental composition). A slight shoul-
der on the acetic acid peak for some of the pooled serum
samples indicated the presence of an unresolved interference.
In PRMmode, different fragment ions were checked to deter-
mine if selecting and monitoring an alternative fragment ion
would remove this interference. This approach was not suc-
cessful, so chromatographic resolution of the interference was
necessary. Several columns were trialled to resolve acetic acid
from the interfering peak. An ACE C18-PFP column with the
same acetonitrile/water gradient program resolved the inter-
ference for acetic acid; however, there was loss of resolution
for isovaleric and its interferences. An ACE C18-AR column
with a modified gradient consisting of water and acetonitrile
as mobile phase successfully resolved acetic acid from its
interference, and at the same time maintained resolution of
the interferences for butyric acid and isovaleric acid
(Fig. 2). Having resolved the acetic acid interference,
it was then possible to determine the potential contribu-
tion of the interference to the acetic acid peak; it varied
from 0 to 12% depending on the sample.
As gas chromatography has traditionally been used to de-
termine SCFAs, particularly for faecal material, the pooled
serum samples were also separated using GC coupled to a
HRAM-MS which was operated in SIM (acetic acid) or
PRM mode (all other analytes) (Fig. 3). The analytes were
quantified as for LC-HRAM-MS and the data are presented
in Table 1. As an orthogonal method, this GC experiment was
completed to determine if there were significant unresolved
interferences in the LC method. Elevated concentrations of
SCFA in the LC data when compared to the GC data would
suggest unresolved interferences. There was generally good
agreement between the LC-HRAM-MS (PRM mode) and the
GC-HRAM-MS (PRM mode) methods (± 20%), particularly
with respect to the relative concentrations of the SCFAs in a
given sample. However, there was a large discrepancy be-
tween the two techniques for isovaleric acid and to a lesser
extent for isobutyric acid, where the GC method reported el-
evated concentrations when compared to the LC meth-
od. This suggested that the interferences visible and
resolved in LC-MS (Fig. 1) are unresolved in GC and
contribute to the analyte signal. No attempt was made
Table 1 Comparison of different methods (full scan, PRM, and SIM on
LC-HRAM-MS and PRM on GC-HRAM-MS) for analysis of SCFAs in
different pooled serum samples (n = 2). SCFAs were separated on a
Thermo Hypersil aQ column (LC-HRAM-MS) and on a Thermo TG-
WAX column (GC-HRAM-MS)
Analyte ISTD Sample LC-HRAM-MS GC-HRAM-MS










Acetic acid 13C2-Acetic acid Pool 1 14,627 558 14,782 31.2 15,110 111 10,064 259
Pool 2 14,933 273 14,872 35.3 15,303 530 12,344 1532
Propionic acid Butyric acid-D7 Pool 1 1271 6.9 2060 90.8 2218 82.6 1188 58.1
Pool 2 1200 13.9 1861 22.3 2085 52.1 1115 94.3
Isobutyric acid Butyric acid-D7 Pool 1 1761 9.4 1749 49.0 1736 18.1 2161 125
Pool 2 1717 12.8 1695 9.3 1716 50.3 2194 173
Butyric acid Butyric acid-D7 Pool 1 1387 10.6 1420 11.4 1410 31 1787 137
Pool 2 1479 25.9 1331 16.4 1354 33.7 1654 141
Isovaleric acid Butyric acid-D7 Pool 1 2766 51.4 2874 37.2 2656 23.7 4387 330
Pool 2 3274 23.1 3334 54.0 3171 78.5 5144 952
Valeric acid 2-Ethylbutyric acid Pool 1 107 1.1 78.2 1.6 78.7 4.0 124 11.3
Pool 2 108 1.6 91.2 1.9 89.6 0.9 115 17.1
4-Methylvaleric acid 2-Ethylbutyric acid Pool 1 15.7 1.3 23.9 1.8 13.9 2.4 23.1 1.9
Pool 2 15.7 1.0 21.6 0.8 13.2 0.0 22.4 1.3
Hexanoic acid 2-Ethylbutyric acid Pool 1 826 22.3 826 8.0 800 131 912 32.9
Pool 2 761 9.3 777 21.8 790 8.6 916 73
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to resolve the interferences in the GC method as the
aim of this work was to develop an LC-MS method.
The use of high-resolution mass spectrometry and orthog-
onal methods when developing methods for analytes in
Fig. 1 Overlay of extracted ion chromatograms of (1) acetic acid, (2)
13C2-acetic acid, (3) propionic acid, (4) isobutyric acid, (5) butyric acid-
D7, (6) butyric acid, (7) isovaleric acid, (8) valeric acid, (9) 2-ethyl butyric
acid, (10) 4-methyl valeric acid, and (11) hexanoic acid of a standard mix
and b pooled serum sample both acquired in PRM mode on a Thermo
Hypersil aQ column (* interference)
Fig. 2 Overlay of extracted ion chromatograms of (1) acetic acid, (2)
13C2-acetic acid, (3) propionic acid, (4) isobutyric acid, (5) butyric acid-
D7, (6) butyric acid, (7) isovaleric acid, (8) valeric acid, (9) 2-ethyl butyric
acid, (10) 4-methyl valeric acid, and (11) hexanoic acid of pooled serum
sample separated on an ACE C18-AR column in PRM (* acetic acid
interference)
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complex matrices such as serum is informative. However, for
routine analysis, tandem mass spectrometry is preferred and
more widely available. The application of this method to a
low-resolution MS instrument, a triple quadrupole, was ex-
plored. The SCFA in five pooled samples were quantitatively
determined using an eight-point calibration curve by
both HR-LC-MS in PRM mode and LC-HRAM-MS in
MRM mode after separation on the ACE C18-AR col-
umn. A similar quantitative ion was selected for most
SCFAs in PRM and MRM with the exception of
isovaleric acid and valeric acid. The transition
236 ➔ 137 for isovaleric acid showed contribution from
an unresolved interference for some samples (Fig. 4).
Therefore, transition 236 ➔ 152 where the interference
Fig. 3 Total ion chromatograms of (1) acetic acid, (2) propionic acid, (3)
isobutyric acid, (4) butyric acid-D7, (5) butyric acid, (6) isovaleric acid,
(7) valeric acid, (8) 2-ethyl butyric acid, (9) 4-methyl valeric acid, and
(10) hexanoic acid in pooled serum sample separated on a Thermo TG-
WAX column in GC-HRAM-MS
Fig. 4 Extracted ion chromatograms of MRM transitions (236 > 137 and 236 > 152) monitored for (1) isovaleric acid and (2) valeric acid on an ACE
C18-AR column in MRM (* interference)
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was not detected was used as the quantitative ion for
the tandem mass spectrometry method (Fig. 4).
There was excellent agreement (95–106%) between the
data obtained from PRM (HRAM instrument) andMRM (tan-
dem MS instrument) modes for acetic, propionic, and
isobutyric acids (Table S5). For butyric acid and isovaleric
acid, there was good agreement (94–117%). However, for
the minor SCFAs, valeric acid and 4-methylvaleric acid were
present at lower concentrations, and typically between 10 and
100 ng mL−1, the agreement was less with the percentage
agreement between 75 and 131% (Table S5). This comparison
of HRAM vs tandem MS after separation on the ACE C18-
AR column was repeated but with 11 individual serum sam-
ples, and again, excellent agreement was obtained for the
SCFAs with the exception of 4-methylvaleric acid, where
the agreement was lower at 71–108% due to its presence in
serum at low concentrations (Table 2). The advantage of using
HRAM-MS to inform the development of a robust method on
a more accessible instrument has been demonstrated.
The LC-MS method was just 15 min long comparing
favourably with other published methods: Song et al. (2019)
separated the SCFAs in 35 min [13], while Wei et al. (2020)
reported a run time of 14 min [11] and Zeng et al. (2018)
reported a run time of just 6 min [10]. The stability of the
SCFA-3-NPH derivatives was previously established by
Han et al. (2015) and was therefore not investigated here [9].
Tandem MS method validation
Linearity, LOD, and LOQ
An eight-point calibration curve was plotted for each analyte
using the ratio of the peak area of the analyte/peak area of IS
versus the ratio of the concentration of the analyte/concentration
of IS. Good linearity was obtained for all analytes over the eval-
uated concentration range (0.015–1 μg mL−1 for valeric acid, 4-
methylvaleric acid, and hexanoic acid; 0.0375–2.5 μg mL−1 for
propionic acid, isobutyric acid, and butyric acid; 0.15–10 μg/mL
for isovaleric acid; and 0.375–25 μg mL−1 for acetic acid) with
correlation coefficients greater than r2 = 0.999 for all analytes.
The limits of detection (LODs) and limits of quantitation
(LOQs) of the method were calculated (Table S3). The concen-
tration range for each of the SCFA in the serum samples tested
varied quite widely—often as much as 100-fold. For example,
the ranges reported in the 11 serum samples tested for isobutyric
acid and isovaleric acid were 90–1241 ng mL−1 and 23–
3992 ng mL−1 respectively. However, the LOQ of the method
for these analytes (3 and 7 ng mL−1 for isobutyric acid and
isovaleric acid respectively) was sufficient and below the lowest
concentration reported. The LOQ for the method was lower than
the concentration detected for all analytes and all serum samples
(pooled and non-pooled) with one exception—one serum sample
reported a concentration for 4-methylvaleric below its LOQ but
above its LOD. Han et al. (2015) measured the 3-NPH deriva-
tives of the SCFAs in faeces, so this work demonstrates that the
derivatising reagent is also sensitive enough for serum applica-
tions, where the concentrations of the SCFAs are several orders
of magnitude lower [9]. Song et al. (2019) selected 4-acetamido-
7-mercapto-2,1,3-benzoxadiazole as the derivatising reagent to
monitor SCFAs in mouse serum, but with LOQs typically 3–10
times higher than reported here, minor SCFAs such as valeric
and isovaleric acid would not be quantifiable in human serum
[13]. Wei et al. (2020) quantified the SCFAs in mouse serum
after derivatisation with d0/d6-N, N-dimethyl-6,7-dihydro-5H-
pyrrolo [3,4-d] pyrimidine-2-amine using HRAM-MS operating
in PRM mode and reported LOQs in the range 0.5–4 fg on
column (for a 10-μL sample injection) [11]. Our LOQs based
on a similar injection volume compare favourable rang-
ing from 1 to 5 fg on column. Zhang et al. (2020)
recently reported a GC-MS method where the SCFAs
extracted from mice serum were derivatised with
BSTFA to improve sensitivity and reported LOQs in
Table 2 Comparison of MRMmode in LC-QQQ and PRMmode in LC-HRAM-MS for quantitative analysis of SCFAs in 11 serum samples. SCFAs
were separated on an ACE C18-AR column





ng mL−1 nM ng mL−1 nM
Acetic acid 3170–12,782 52,788–212,849 3100–13,015 51,622–216,729 86.4–109
Propionic acid 360–1136 4860–15,335 350–1156 4725–15,605 93.7–103
Isobutyric acid 90–1241 1021–14,085 100–1211 1135–13,745 90–105
Butyric acid 122–1247 1385–14,153 124–1247 1407–14,153 93.9–109
Isovaleric acid 23.5–3992 230–39,086 23.5–3932 230–38,499 92.7–110
Valeric acid 20–100 196–979 21–106 206–1038 91.5–110
4-Methylvaleric acid 3.8–12 33–103 3.7–14 31.8–120.5 71.4–108
Hexanoic acid 30–391 258–3366 27–385 232–3314 95.7–111
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the range 100–200 ng/mL which are at least an order of
magnitude higher than reported here [5].
Precision, trueness, and accuracy
Intra- and inter-day variations were determined by analysing eight
different concentrations of calibration standards for six replicates in
a single day (intra-day) and one replicate for six consecutive days
(inter-day) to evaluate the precision (% CV) and trueness (% bias)
of the developed analytical method. The CV ranged from 0.34 to
12.58% and the bias for both intra-day and inter-day studies was
within ± 20% with the exception of propionic acid at
0.25 μg mL−1, where the % bias was 23.29% (Table S3).
Retention time repeatability for each analyte was deter-
mined by calculating the %RSD from the obtained retention
time after 12 injections. The %RSDs were less than 0.3% and
as low as 0.02%. Specifically, the %RSDs for retention time
repeatability were 0.29, 0.20, 0.04, 0.06, 0.04, 0.03, 0.05, and
0.02 for acetic acid, propionic acid, isobutyric acid, butyric
acid, isovaleric acid, valeric acid, 4-methyl valeric acid, and
hexanoic acid, respectively.
The accuracy of the method was determined by recovery
study. The recovery of the SCFAs in serum ranged from 93.97
to 113.81% in this study and over the three concentration
ranges tested (Table S4) and compared very favourably with
recent methods for analysis of SCFAs in serum by LC-MS.
Song et al. (2019) reported recoveries ranging between 82 and
116% [13], and Wei et al. (2020) reported recoveries of be-
tween 80 and 120% [11] for the determination of SCFA in
mouse serum, and using LC-MS.
Conclusion
The focus of this work was to highlight the role of high-
resolution mass spectrometry and orthogonal methods in
method development particularly when the matrix is complex
and the analytes are present at low concentrations. A method
for the determination of SCFAs in serum is reported using a
reversed-phase column for separation and MS for detection.
The presence of several interferences was detected using high-
resolution mass spectrometry. Chromatographic separation
was necessary to resolve the interferences using a C18 column
with embedded aromatic functionality (ACE C18-AR col-
umn). The HRAM-MS method was successfully transferred
to a QQQmethod. The latter method was validated using both
pooled and individual serum samples.
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